Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human vaginal metagenome

ABSTRACT: Key Vaginal Bacteria Associated with Increased Risk of HIV Acquisition in African Women

PROVIDER: PRJNA420364 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6338340.fastq.gz	Fastqsanger.gz
	SRR6338350.fastq.gz	Fastqsanger.gz
	SRR6338360.fastq.gz	Fastqsanger.gz
	SRR6338370.fastq.gz	Fastqsanger.gz
	SRR6338380.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 110

Similar Datasets

Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in humans and increases susceptibility to HIV-1 in humanized mice

Project description:The hormonal contraceptive medroxyprogesterone acetate (MPA) is associated with increased risk of human immunodeficiency virus (HIV), via incompletely understood mechanisms. Increased diversity in the vaginal microbiota modulates genital inflammation and is associated with increased HIV-1 acquisition. However, the effect of MPA on diversity of the vaginal microbiota is relatively unknown. In a cohort of female Kenyan sex workers, negative for sexually transmitted infections (STIs), with Nugent scores <7 (N=58 of 370 screened), MPA correlated with significantly increased diversity of the vaginal microbiota as assessed by 16S rRNA gene sequencing. MPA was also significantly associated with decreased levels of estrogen in the plasma, and low vaginal glycogen and α-amylase, factors implicated in vaginal colonization by lactobacilli, bacteria that are believed to protect against STIs. In a humanized mouse model, MPA treatment was associated with low serum estrogen, low glycogen and enhanced HIV-1 susceptibility. The mechanism by which the MPA mediated changes in the vaginal microbiota may contribute to HIV-1 susceptibility in humans appears to be independent of inflammatory cytokines and/or activated T cells. Altogether, these results suggest MPA-induced hypo-estrogenism may alter key metabolic components that are necessary for vaginal colonization by certain bacterial species including lactobacilli, and allow for greater bacterial diversity in the vaginal microbiota.

2019-10-17 | GSE138971 | GEO

human vaginal metagenome (1632839)

Project description:Vaginal Bacteria and Soluble Immune Mediators Associated with HIV Acquisition Risk Among African Women: A Nested Case-Control Study

| PRJNA881335 | ENA

Global Expression of Molecular Transporters in the Human Vaginal Tract

Project description:Pre-exposure chemoprophylaxis using antiretroviral agents is a promising strategy for the prevention of sexual HIV transmission in women. Molecular transporters in the human vaginal tract may play a pivotal role in determining drug disposition and, consequently, pharmacodynamic outcomes in these efforts. Little is known, however, on the expression of these transporters in vaginal tissues, representing a critical knowledge gap. Our study analyzed the genome-wide transcriptome in 44 vaginal tissue samples from 6 reproductive-age women undergoing gynecologic surgeries. The genome-wide transcriptome in 44 vaginal tissue samples from 6 reproductive-age women (20-56 years old) undergoing gynecologic surgeries was measured.

2014-01-29 | E-GEOD-49892 | biostudies-arrayexpress

Global Expression of Molecular Transporters in the Human Vaginal Tract

2014-01-29 | GSE49892 | GEO

human vaginal metagenome

Project description:Association of vaginal bacteria with risk of Trichomonas vaginalis acquisition

| PRJNA548797 | ENA

Results of the phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel

Project description:Griffithsin (GRFT) is an anti-viral lectin with potent anti-HIV activity. GRFT’s preclinical safety, lack of systemic absorption after topical administration, and lack of cross-resistance with existing products prompted its development for topical HIV pre-exposure prophylaxis. We evaluated safety, pharmacokinetics and pharmacodynamics of PC-6500 (0.1% GRFT in a carrageenan (CG) gel) in healthy, HIV-negative, non-pregnant women following once daily vaginal gel administration for 14 days. No significant adverse events, histopathological changes in cervico-vaginal mucosa, or anti-drug (GRFT) antibodies were detected. No cervicovaginal proinflammatory responses and no changes in the ectocervical transcriptome were evident. Vaginal microbiome remained largely unchanged. Reduced abundance of vaginosis-associated bacteria and decreased levels of proinflammatory chemokines (CXCL8 and CCL20) were observed. GRFT was not detected in plasma. GRFT and GRFT/CG in CVLs dose-dependently inhibited HIV and HPV, respectively, in vitro. The data suggest GRFT/CG is a promising on-demand multipurpose prevention product that warrants further investigation.

2021-10-04 | GSE141478 | GEO

Human vaginal metagenome

Project description:Vaginal microbiome of South African women

| PRJNA767784 | ENA

human vaginal metagenome

Project description:Vaginal microbiome of Canadian HIV+ women

| PRJNA362575 | ENA

HIV gp120 modulates the vaginal transcriptome

Project description:During sexual transmission of HIV-1 from male to female partners, the vagina is the initial site of contact with HIV infected semen. The mechanism of HIV traversing the CD4 negative multi-layered stratified squamous epithelial barrier of the vagina to infect sub-epithelial susceptible immune cells, is hitherto unknown. HIV gp120 binds to several host proteins on vaginal epithelial cells. To gain an insight into the physiologic changes that may occur in vaginal epithelial cells in response to interactions with HIV gp120, and obtain an understanding of the molecular mechanisms by which HIV breaches the vaginal epithelium, a global snap shot of gene expression profiles in the vaginal epithelial cell line Vk2/E6E7, treated with HIV gp120 was determined. The vaginal epithelial cell line Vk2/E6E7 was treated with HIV gp120 (83nM) for 24 hr, and Agilent one colour, microarrays were performed.

2014-03-01 | GSE44914 | GEO

Cervicovaginal bacteria impact HIV acquisition in young African women

Project description:Cervicovaginal bacteria impact HIV acquisition in young African women

| PRJEB14858 | ENA